Citations

Clear

6273 citation(s) found for "To, Andrew".

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Abida, Wassim , Chatta, Gurkamal , Dawson, Nancy A. , Guancial, Elizabeth A. , Hussain, Arif , Jha, Gautam , Lipsitz, David, Petrylak, Daniel P. , Ryan, Charles J. , Stanton, T., Zhang, Jingsong , Simmons, Andrew D. , Go, Jowell, Golsorkhi, Tony, Chowdhury, Simon, Scher, Howard I. , Bryce, Alan H. , Balar, Arjun Vasant , Patnaik, Akash , Vogelzang, Nicholas J.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS388-TPS388

10.1200/jco.2018.36.6_suppl.tps388 Get It

TPS388 Background: Up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM or another homologous recombination (HR) DNA repair gene that can serve as a molecular marker to select those who may respond to poly(ADP-ribose) polymerase inhibitors (PARPis). PARPis are lethal to cells with HRD, and PARPi treatment has shown preliminary evidence of an antitumor effect in patients with mCRPC who harbor a mutation in an HR DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with HRD. Methods: TRITON2 (NCT02952534) is a phase 2 study evaluating rucaparib 600 mg BID in patients with mCRPC. Patients with a deleterious germline or somatic BRCA1, BRCA2 or ATM mutation (per prior local test or central test during screening) will be enrolled into 1 of 2 cohorts based on the presence or absence of measurable visceral and/or nodal disease. An exploratory cohort will enroll patients with an alteration in any of 12 other prespecified HR genes (eg, RAD51C, RAD51D and PALB2), with or without measurable visceral and/or nodal disease. Patients must have progressed on androgen receptor signaling–directed therapy and 1 prior taxane-based chemotherapy for mCRPC. Patients who received prior treatment with a PARPi, mitoxantrone, cyclophosphamide or platinum-based chemotherapy are excluded. The primary endpoint is objective response rate measured using modified RECIST v1.1/PCWG3 for patients with soft-tissue disease and prostate-specific antigen response for patients with nonmeasurable disease. Secondary endpoints include duration of response, radiographic progression-free survival, overall survival, clinical benefit rate and safety. Pretreatment blood samples collected from all patients will enable development of a plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈160) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02952534.
Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.
Tendulkar, Rahul D. , Niemierko, Andrzej , Stephans, Kevin L. , Lee, W. Robert , Michalski, Jeff M. , Pisansky, Thomas M. , Pollack, Alan , Zietman, Anthony L., Stephenson, Andrew J. , Hwang, William L. , Agrawal, Shree , Spratt, Daniel E. , Hearn, Jason W.D. , Koontz, Bridget F. , Liauw, Stanley L. , Abramowitz, Matthew C. , Moghanaki, Drew M. , Anscher, Mitchell S. , Den, Robert B. , Efstathiou, Jason A.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: 24-24

10.1200/jco.2018.36.6_suppl.24 Get It

24 Background: The use of radical prostatectomy (RP) as initial treatment of high-risk/locally-advanced prostate cancer is increasing but patients (pts) with adverse pathologic features such as positive surgical margins or T3 disease have up to 70% recurrence risk. These high-risk pts may be managed with adjuvant radiotherapy (ART) or early salvage radiotherapy (ESRT). The optimal timing of post-operative radiotherapy is unclear. Methods: Individual data from 1566 consecutive pts with pT2N0M0/R1 or pT3N0M0/R0-1 disease who underwent post-prostatectomy ART or ESRT (1987-2013) at 10 academic centers were pooled. Post-irradiation freedom from biochemical failure (FFBF), freedom from distant metastases (FFDM), prostate-cancer specific survival (PCSS), and overall survival (OS) were compared using Kaplan-Meier and multivariate competing-risks regression (MVA) analyses. Propensity score (PS) matching was used to account for covariates potentially associated with treatment allocation. All outcomes were measured from the date of surgery to address lead time bias. Results: After PS-matching, median follow-up after surgery was 66 vs. 73 months for the ART and ESRT groups, respectively, and baseline characteristics were well-matched. ART was associated with higher FFBF (12-yr: 69% vs. 43%; log-rank P < 0.0001), FFDM (12-yr: 95% vs. 85%; log-rank P = 0.03), PCSS (12-yr: 99% vs. 94%; log-rank P = 0.048), and OS (12-yr: 91% vs. 79%; log-rank P = 0.01). ART, lower Gleason score, lower T-stage, nodal irradiation, and postoperative androgen deprivation therapy were favorable prognostic features on MVA for BF. Sensitivity analysis demonstrated that the decreased risk of BF associated with ART remained significant unless more than 56% of ART pts were cured by surgery alone. This threshold is greater than the estimated 12-yr FFBF of 46% after RP alone as determined by a contemporary nomogram. Conclusions: To the best of our knowledge, this represents the largest multi-institutional study to date comparing ART to ESRT. ART was associated with reduced biochemical recurrence, distant metastases, and death compared to ESRT for high-risk pts, pending prospective validation.
Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.
Alshalalfa, Mohammed , Mehra, Rohit , Rayford, Walter, Erho, Nicholas , Dicker, Adam P. , Freedland, Stephen J. , Karnes, Jeffrey , Glass, Andrew G., Weinmann, Sheila , Ross, Ashley E. , Feng, Felix Y. , Schaeffer, Edward M. , Spratt, Daniel E. , Weiner, Adam B. , Fishbane, Nick , Davicioni, Elai , Den, Robert B. , Dicker, Adam P

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: 2-2

10.1200/jco.2018.36.6_suppl.2 Get It

2 Background: Significant genomic diversity exists in the androgen receptor ( AR) and its activity (AR-A) in mCRPC. In localized prostate cancer, the biologic, prognostic, and therapeutic clinical implications of AR-A heterogeneity have yet to be interrogated Methods: Genome-wide expression profiles of FFPE RP or biopsy tumor samples were evaluated from a prospective registry cohort (n = 5,239, NCT02609269) and six retrospective institutional cohorts (n = 1,170). AR-A was calculated based on expression of 9 targets of AR.. Results: Utilizing 6,409 localized prostate adenocarcinomas with full transcriptomic data, we found there was marked inter-individual transcriptomic diversity in AR and AR-A expression, and weak correlation between them (r = 0.08 to 0.36 based on cohort), in contrast to mCRPC that has a strong correlation between AR and AR-A expression (r = 0.76). Additionally, serum PSA had no correlation to intratumoral AR-A (r = 0.06). Unsupervised hierarchical clustering identified a distinct subclass of low AR-A prostate tumors, which had increased markers of immunogenicity (decreased T-regs and MDSCs, and increased CD3 effector T-cells), increased neuroendocrine marker expression ( NCAM1, ENO2, and SCG2), and decreased DNA repair pathway expression (all p < 0.001). Clinically, low AR-A tumors had more rapid development of metastatic disease in three independent cohorts, were more prone to develop resistance to hormonal therapy and develop CRPC, and were found at an increased frequency in African-American men. Interrogating in vitro drug sensitivity analyses utilizing the NCI-60 panel, low AR-A tumors appear more sensitive to platinum chemotherapy and PARP inhibition, and less sensitive to hormone therapy and taxanes. Conclusions: The diversity in AR-signaling in localized prostate cancer represents important biological heterogeneity that is both prognostic and predictive of treatment response. These findings are provocative in that low AR-A tumors may be more susceptible to immunotherapy, PARP inhibition, platinum chemotherapy, and/or radiotherapy. Patients with low AR-A tumors warrant dedicated biomarker enhanced clinical trials.
Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial
Chen, John J. , Majed, Masoud , Jitprapaikulsan, Jiraporn , Fryer, James P., Leavitt, Jacqueline A., McKeon, Andrew , Pittock, Sean J. , Pittock, S J , McKeon, Andrew , Chen, John J , Tobin, W. Oliver , Flanagan, Eoin P.

Mayo Clinic

JAMA Ophthalmology | February 22, 2018 | Volume: 136 | Issue: 4 | Pages: 419

10.1001/jamaophthalmol.2017.6757 | PMID 29470571 Get It

Aging and anatomical variations in lung tissue stiffness
Sicard, Delphine , Haak, Andrew J. , Choi, Kyoung Moo , Craig, Alexandria R., Fredenburgh, Laura E. , Tschumperlin, Daniel J.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | February 22, 2018 | Volume: 314 | Issue: 6 | Pages: L946-L955

10.1152/ajplung.00415.2017 | PMID 29469613 Get It

Lung function is inherently mechanical in nature and depends on the capacity to conduct air and blood to and from the gas exchange regions. Variations in the elastic properties of the human lung across anatomical compartments and with aging are likely important determinants of lung function but remain relatively poorly characterized. Here we applied atomic force microscopy microindentation to characterize human lung tissue from subjects ranging in age from 11 to 60 yr old. We observed striking anatomical variations in elastic modulus, with the airways (200- to 350-µm diameter) the stiffest and the parenchymal regions the most compliant. Vessels (diameter < 100 µm) represented an intermediate mechanical environment and displayed diameter-dependent trends in elastic modulus. Binning our samples into younger (11–30 yr old) and older (41–60 yr old) groups, we observed significant age-related increases in stiffness in parenchymal and vessel compartments, with the most pronounced changes in the vessels. To investigate cellular mechanisms that might contribute to vascular stiffening with aging, we studied primary human pulmonary artery smooth muscle cells from subjects ranging in age from 11 to 60 yr old. While we observed no change in the mechanical properties of the cells themselves, we did observe trends toward increases in traction forces and extracellular matrix deposition with aging. These results demonstrate age-related changes in tissue mechanical properties that likely contribute to impaired lung function with aging and underscore the potential to identify mechanisms that contribute to mechanical tissue remodeling through the study of human cells and tissues from across the aging spectrum.
Total elbow arthroplasty after previous resection of the radial head and synovectomy
Whaley, Andrew L., Morrey, B.F. , Adams, Robert

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | February 21, 2018 | Volume: 87-B | Issue: 1 | Pages: 47-53

10.1302/0301-620x.87b1.14543 Get It

We examined the effects of previous resection of the radial head and synovectomy on the outcome of subsequent total elbow arthroplasty in patients with rheumatoid arthritis. Fifteen elbows with a history of resection and synovectomy were compared with a control group of patients who had elbow arthroplasty with an implant of the same design. The mean age in both groups was 63 years. In the study group, resection of the radial head and synovectomy had been undertaken at a mean of 8.9 years before arthroplasty. The mean radiological follow-up for the 13 available patients in the study group was 5.89 years (0.3 to 11.0) and in the control group was 6.6 years (2.2 to 12.6). There were no revisions in either group. The mean Mayo elbow performance score improved from 29 to 96 in the study group, with similar improvement in the control group (28 to 87). The study group had excellent results in 13 elbows and good results in two. The control group had excellent results in seven and good results in six. Our experience indicates that previous resection of the radial head and synovectomy are not associated with an increased rate of revision following subsequent arthroplasty of the elbow. However, there was a higher rate of complication in the study group compared with the control group.
Computed tomography analysis of frontal cell prevalence according to the International Frontal Sinus Anatomy Classification
Thamboo, Andrew , Won, Tae‐Bin , Kim, Jooyeon , Shih, Liang Chun, Hwang, Peter H. , Patel, Zara M. , Patel, Zara , Choby, Garret , Hwang, Peter H

Mayo Clinic

International Forum of Allergy & Rhinology | February 21, 2018 | Volume: 8 | Issue: 7 | Pages: 825-830

10.1002/alr.22105 | PMID 29457874 Get It

BackgroundThe International Frontal Sinus Anatomy Classification (IFAC) is an international consensus document published in 2016 to standardize the nomenclature of cells in the region of the frontal recess and frontal sinus. The IFAC was designed to be surgically relevant and anatomically precise. The current study was undertaken to assess the prevalence of the frontal cell variants as defined by the IFAC, as well as to determine the interrater reliability of the IFAC.MethodsThree independent reviewers examined triplanar nondiseased maxillofacial computed tomography (CT) scans to assess the anatomy of the frontal recess according to the IFAC system. The prevalence of each cell type was assessed and interrater reliability was measured using an intraclass correlation coefficient (ICC).ResultsOne hundred CT scans (200 sides) were examined. Of the 200 sides, 96.5% contained an agger nasi cell (ICC, 0.82; 95% confidence interval [CI], 0.77‐0.86), 30.0% contained a supra agger cell (ICC, 0.89; 95% CI, 0.86‐0.92), 20.0% contained a supra agger frontal cell (ICC 0.80; 95% CI 0.74‐0.84), 72.0% contained a supra bulla cell (ICC, 0.81; 95% CI, 0.76‐0.85), 5.5% contained a supra bulla frontal cell (ICC, 0.71; 95% CI, 0.63‐0.77), 28.5% contained a supraorbital ethmoid cell (ICC, 0.78; 95% CI, 0.72‐0.83), and 30.0% contained a frontal septal cell (ICC, 0.80; 95% CI, 0.74‐0.84). The ICC was good to excellent for identification of all frontal cell types.ConclusionsThis study describes the normative distribution of frontal recess cells in a nondiseased population according to IFAC and demonstrates favorable interrater reliability of the classification system.
Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement
Fundakowski, Christopher , Hales, Nathan W., Agrawal, Nishant , Camacho, Pauline M., Hartl, Dana M. , Kandil, Emad , Liddy, Whitney , McKenzie, Travis J. , Morris, John C., Schneider, Rick , Serpell, Jonathan W. , Sinclair, Catherine F. , Terris, David J. , Tuttle, R. Michael , Wu, Che‐Wei , Zafereo, Mark , Fundakowski, Christopher E , Barczyński, Marcin , Ridge, John Andrew , Snyder, Susan M. , Wong, Richard J. , Randolph, Gregory William

Mayo Clinic

Head & Neck | February 21, 2018 | Volume: 40 | Issue: 4 | Pages: 663-675

10.1002/hed.24928 | PMID 29461666 Get It

Abstract “I have noticed in operations of this kind, which I have seen performed by others upon the living, and in a number of excisions, which I have myself performed on the dead body, that most of the difficulty in the separation of the tumor has occurred in the region of these ligaments…. This difficulty, I believe, to be a very frequent source of that accident, which so commonly occurs in removal of goiter, I mean division of the recurrent laryngeal nerve.” Sir James Berry (1887)
Fatty acid synthase is required for profibrotic TGF‐β signaling
Kang, Jeong Han , Hernandez, Danielle M. , Yin, Xueqian , Andrianifahanana, Mahefatiana, González-Guerrico, Anatilde M., Leof, Edward B. , Jung, Mi-Yeon, Gonzalez-Guerrico, Anatilde, Lupu, Ruth , Jung, Miyeon , Wang, Youli , Limper, Andrew H.

Mayo Clinic

The FASEB Journal | February 16, 2018 | Volume: 32 | Issue: 7 | Pages: 3803-3815

10.1096/fj.201701187r | PMID 29475397 Get It

Evidence is provided that the fibroproliferative actions of TGF‐β are dependent on a metabolic adaptation that sustains pathologic growth. Specifically, profibrotic TGF‐β signaling is shown to require fatty acid synthase (FASN), an essential anabolic enzyme responsible for the de novo synthesis of fatty acids. With the use of pharmacologic and genetic approaches, we show that TGF‐β‐stimulated FASN expression is independent of Smad2/ 3 and is mediated via mammalian target of rapamycin complex 1. In the absence of FASN activity or protein, TGF‐β ‐driven fibrogenic processes are reduced with no apparent toxicity. Furthermore, as increased FASN expression was also observed to correlate with the degree of lung fibrosis in bleomycin‐treated mice, inhibition of FASN was examined in a murine‐treatment model of pulmonary fibrosis. Remarkably, inhibition of FASN not only decreased expression of profibrotic targets, but lung function was also stabilized/improved, as assessed by peripheral blood oxygenation.—Jung, M.‐Y., Kang, J.‐H., Hernandez, D. M., Yin, X., Andrianifahanana, M., Wang, Y., Gonzalez‐Guerrico, A., Limper, A. H., Lupu, R., Leof, E. B. Fatty acid synthase is required for profibrotic TGF‐β signaling. FASEB J. 32, 3803–3815 (2018). www.fasebj.org
Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer
Lei, JT, Shao, Jieya , Zhang, J, Iglesia, Michael D. , Cao, Jin , Haricharan, Svasti , Kavuri, SM, Matsunuma, Ryoichi , Schmidt, Cecilia, Kosaka, Yoshimasa , Crowder, RJ, Hoog, J, Phommaly, Chanpheng, Gonçalves, Rodrigo , Ramalho, Susana , Rodrigues-Peres, RM, Lai, W-C, Rogers, Anna , Tobias, Ethan, Parikh, Poojan A., Davies, S. J. , Ma, C, Suman, VJ, Watson, Mark , Hoadley, KA, Thompson, Andrew , Perou, CM, Creighton, CJ, Ellis, MJ, Chan, David W. , Anurag, Meenakshi , Singh, Pankaj Kumar , Hampton, Oliver , Ma, C, Hunt, Kelly K. , Watson, M, Hoadley, Katherine A. , Maher, Christopher G.

Mayo Clinic

Cancer Research | February 15, 2018 | Volume: 78 | Issue: 4_Supplement | Pages: PD8-03-PD8-03

10.1158/1538-7445.sabcs17-pd8-03 Get It

Abstract Background. Dysregulation of the estrogen receptor gene (ESR1) is an established mechanism of inducing endocrine therapy resistance. We previously discovered a chromosomal translocation event generating an estrogen receptor gene fused in-frame to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer models. This study compares functional, transcriptional, and pharmacological properties of additional ESR1 gene fusion events of both early stage (ESR1-NOP2) late stage (ESR1-YAP1 and ESR1-PCDH11x) breast cancers to gain a better understanding of therapeutic resistance and metastasis. Understanding the role of ESR1 fusions in inducing metastasis is critical, since the primary cause of death in breast cancer patients is through metastasis to distant sites. Methods. RNA-seq screens identified ESR1 fusions from early and late stage, endocrine therapy resistant breast tumor samples. Functional experiments were conducted using ER+ breast cancer cell lines, xenograft, and PDX models to test the ability of ESR1 fusions to induce therapeutic resistance and metastasis. ChIP-seq and RNA-seq were performed to examine transcriptional properties and differential gene expression induced by the fusions which directed subsequent pharmacological experiments with a CDK4/6 inhibitor. Results. ESR1-YAP1 and ESR1-PCDH11x promoted estrogen-independent and fulvestrant-resistant growth in vitro and induced greater tumor growth and increased metastatic capacity to the lungs of xenografted mice. In contrast, the ESR1-NOP2 fusion was sensitive to low estrogen conditions in vitro, and did not promote tumor growth. RNA-seq profiling revealed E2F targets pathway as the most highly enriched pathway induced by the ESR1 fusions. IHC revealed higher levels of pRb in ESR1-YAP1 and ESR1-PCDH11x xenograft tumors and subsequent CDK4/6 inhibition completely blocked tumor growth in an ESR1-YAP1 PDX model. Integrating RNA-seq with ChIP-seq data, we discovered a set of EMT and metastasis genes bound by all ESR1 fusions and WT-ER, but whose expression was strongly and uniquely up-regulated only by the ESR1-YAP1 and ESR1-PCDH11x fusions. These studies also revealed gained sites bound only by the ESR1-YAP1 and ESR1-PCDH11x fusions, not bound by WT-ER nor ESR1-NOP2. Genes mapping to these sites have a role in metastatic biology and were highly up-regulated by the YAP1 and PCDH11x fusions, potentially mediated by long range transcriptional activation. Conclusion. ESR1-YAP1 and ESR1-PCDH11x are driver fusions that occur in drug-resistant, advanced stage breast cancer and are a new class of recurrent somatic mutation that can cause acquired endocrine therapy resistance, yet can be treated with CDK4/6 inhibition. These driver fusions also confer increased metastatic ability through their ability to drive expression of genes that contribute to EMT and metastasis. In contrast, ESR1-NOP2 did not produce functional protein and appears to be a passenger event. These studies may provide pre-clinical rationale for targeting ESR1 translocated breast tumors, since the presence of an ESR1 driver fusion places a patient in a therapeutic category where none of the currently available endocrine therapies are likely to be effective. Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD8-03.